|
Mechanism5-HT2A receptor antagonists [+2] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date01 Jan 1985 |
A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis.
Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis.
100 Clinical Results associated with Douglas Pharmaceuticals America Ltd.
0 Patents (Medical) associated with Douglas Pharmaceuticals America Ltd.
100 Deals associated with Douglas Pharmaceuticals America Ltd.
100 Translational Medicine associated with Douglas Pharmaceuticals America Ltd.